Literature DB >> 1908745

Immunoglobulin subclasses and prophylactic use of immunoglobulin in immunoglobulin G subclass deficiency.

T Söderström1, R Söderström, A Enskog.   

Abstract

Persistent low serum levels of one or several immunoglobulin G (IgG) subclasses can be found in a high proportion of adult patients with increased susceptibility to infections. It is hard to envision that the low subclass level in itself is responsible for this susceptibility because healthy blood donors have been described who are completely devoid of certain subclasses in serum. This apparent discrepancy may be partly explained by the observation that most subclass-deficient patients have underlying aberrations in T-cell and B-cell interaction and function that may impair their capacity to compensate for even minor deficiencies. A prospective blind crossover study of the effect of prophylactic Ig substitution therapy was done in 43 adult patients with IgG subclass deficiency. The patients were randomized to receive 1 year of therapy with intramuscular Ig 25 mg/kg/wk or 1 year of saline injections. A significant protective effect of the prophylactic Ig therapy was seen with a great reduction in the number of days of infection. In addition, several immunologic parameters were altered after 1 year of Ig therapy. Nineteen of the patients later were included in an open study using 50 mg/kg/wk of Ig. After 6 months of treatment, significant protection against infection was observed, with a reduction of 6.2 days in the number of days per month with infection. This marked effect of prophylactic Ig suggests that the Ig aberrations seen in IgG subclass-deficient patients contributed to their susceptibility to infection. The effect of 25 mg/kg/wk was much less pronounced than that of 50 mg/kg/wk, and normal serum IgG subclass levels were not achieved even during the higher-dose therapy. However, it seems likely that subcutaneous or intravenous administration of larger doses of Ig would allow for more efficient therapy.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1908745     DOI: 10.1002/1097-0142(19910915)68:6+<1426::aid-cncr2820681404>3.0.co;2-r

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  6 in total

1.  Development, manufacturing and characterization of a highly purified, liquid immunoglobulin g preparation from human plasma.

Authors:  Inga A Laursen; Lene Blou; John S Sullivan; Peter Bang; Flemming Balstrup; Gunnar Houen
Journal:  Transfus Med Hemother       Date:  2014-04-14       Impact factor: 3.747

2.  Symptomatic IgG3 deficiency successfully treated with intravenous immunoglobulin therapy.

Authors:  J A Snowden; A Milford-Ward; J T Reilly
Journal:  Postgrad Med J       Date:  1994-12       Impact factor: 2.401

3.  Immunoglobulin G subclass deficiency is the major phenotype of primary immunodeficiency in a Korean adult cohort.

Authors:  Joo-Hee Kim; Han-Jung Park; Gil-Soon Choi; Jeong-Eun Kim; Young-Min Ye; Dong-Ho Nahm; Hae-Sim Park
Journal:  J Korean Med Sci       Date:  2010-05-24       Impact factor: 2.153

4.  Prospective, randomized comparison of OM-85 BV and a prophylactic antibiotic in children with recurrent infections and immunoglobulin A and/or G subclass deficiency.

Authors:  Ferah Genel; Necil Kutukculer
Journal:  Curr Ther Res Clin Exp       Date:  2003-09

5.  Recurrent C. difficile in a Patient with IgG Deficiency.

Authors:  Asad Jehangir; Kyle Bennett; Shoaib Bilal Fareedy; Andrew Rettew; Bilal Shaikh; Anam Qureshi; Qasim Jehangir; Richard Alweis
Journal:  Case Rep Gastrointest Med       Date:  2015-04-05

6.  Primary IgA and IgG subclass deficiency in a 17-year-old Pakistani girl: a case report.

Authors:  Taimur Saleem; Madiha Rabbani; Bushra Jamil
Journal:  Cases J       Date:  2009-08-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.